## Jian-Yong Shao

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2477006/publications.pdf

Version: 2024-02-01

279798 168389 2,883 60 23 53 citations g-index h-index papers 60 60 60 4353 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. Rna, 2008, 14, 2348-2360.	3.5	993
2	Comparison of plasma Epstein–Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma. Cancer, 2004, 100, 1162-1170.	4.1	194
3	Plasma Epstein-Barr virus DNA level strongly predicts survival in metastatic/recurrent nasopharyngeal carcinoma treated with palliative chemotherapy. Cancer, 2011, 117, 3750-3757.	4.1	134
4	Eight-Signature Classifier for Prediction of Nasopharyngeal Carcinoma Survival. Journal of Clinical Oncology, 2011, 29, 4516-4525.	1.6	131
5	The Prognostic Value of Plasma Epstein-Barr Viral DNA and Tumor Response to Neoadjuvant Chemotherapy in Advanced-Stage Nasopharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics, 2015, 93, 862-869.	0.8	110
6	A new prognostic histopathologic classification of nasopharyngeal carcinoma. Chinese Journal of Cancer, 2016, 35, 41.	4.9	83
7	Genome-Wide Identification of a Methylation Gene Panel as a Prognostic Biomarker in Nasopharyngeal Carcinoma. Molecular Cancer Therapeutics, 2015, 14, 2864-2873.	4.1	80
8	Active and Passive Smoking and Risk of Nasopharyngeal Carcinoma: A Population-Based Case-Control Study in Southern China. American Journal of Epidemiology, 2017, 185, 1272-1280.	3.4	68
9	Plasma Epstein-Barr Virus DNA Load After Induction Chemotherapy Predicts Outcome in Locoregionally Advanced Nasopharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics, 2019, 104, 355-361.	0.8	64
10	Knockdown of miR-214 Promotes Apoptosis and Inhibits Cell Proliferation in Nasopharyngeal Carcinoma. PLoS ONE, 2014, 9, e86149.	2.5	62
11	Serum micro <scp>RNA</scp> profiles as diagnostic biomarkers for <scp>HBV</scp> â€positive hepatocellular carcinoma. Liver International, 2017, 37, 888-896.	3.9	56
12	The Prognostic Value of Treatment-Related Lymphopenia in Nasopharyngeal Carcinoma Patients. Cancer Research and Treatment, 2018, 50, 19-29.	3.0	56
13	Quantification of familial risk of nasopharyngeal carcinoma in a highâ€incidence area. Cancer, 2017, 123, 2716-2725.	4.1	54
14	SPINK6 Promotes Metastasis of Nasopharyngeal Carcinoma via Binding and Activation of Epithelial Growth Factor Receptor. Cancer Research, 2017, 77, 579-589.	0.9	47
15	Oral Hygiene and Risk of Nasopharyngeal Carcinoma—A Population-Based Case–Control Study in China. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1201-1207.	2.5	46
16	TEL2 suppresses metastasis by down-regulating SERPINE1 in nasopharyngeal carcinoma. Oncotarget, 2015, 6, 29240-29253.	1.8	39
17	Plasma Epstein-Barr viral DNA complements TNM classification of nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy. Oncotarget, 2016, 7, 6221-6230.	1.8	37
18	Neoadjuvant chemotherapy in locally advanced nasopharyngeal carcinoma: Defining high-risk patients who may benefit before concurrent chemotherapy combined with intensity-modulated radiotherapy. Scientific Reports, 2015, 5, 16664.	3.3	34

#	Article	IF	CITATIONS
19	Comparison of Long-Term Survival and Toxicity of Cisplatin Delivered Weekly versus Every Three Weeks Concurrently with Intensity-Modulated Radiotherapy in Nasopharyngeal Carcinoma. PLoS ONE, 2014, 9, e110765.	2.5	31
20	Development of a Nomogram Model for Treatment of Nonmetastatic Nasopharyngeal Carcinoma. JAMA Network Open, 2020, 3, e2029882.	5.9	31
21	MicroRNA-30a promotes invasiveness and metastasis <i>inÂvitro</i> and <i>inÂvivo</i> through epithelial–mesenchymal transition and results in poor survival of nasopharyngeal carcinoma patients. Experimental Biology and Medicine, 2014, 239, 891-898.	2.4	29
22	Concurrent chemoradiotherapy with or without cetuximab for stage II to IVb nasopharyngeal carcinoma: a case–control study. BMC Cancer, 2017, 17, 567.	2.6	29
23	Development of a population-based cancer case-control study in southern china. Oncotarget, 2017, 8, 87073-87085.	1.8	29
24	Past and Recent Salted Fish and Preserved Food Intakes Are Weakly Associated with Nasopharyngeal Carcinoma Risk in Adults in Southern China. Journal of Nutrition, 2019, 149, 1596-1605.	2.9	25
25	Serum microRNA profiles as prognostic biomarkers for HBV-positive hepatocellular carcinoma. Oncotarget, 2016, 7, 45637-45648.	1.8	22
26	Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival. Chinese Journal of Cancer, 2015, 34, 225-34.	4.9	21
27	The impact of the cumulative dose of cisplatin during concurrent chemoradiotherapy on the clinical outcomes of patients with advanced-stage nasopharyngeal carcinoma in an era of intensity-modulated radiotherapy. BMC Cancer, 2015, 15, 977.	2.6	21
28	High expression of Talin-1 is associated with poor prognosis in patients with nasopharyngeal carcinoma. BMC Cancer, 2015, 15, 332.	2.6	21
29	Medical History, Medication Use, and Risk of Nasopharyngeal Carcinoma. American Journal of Epidemiology, 2018, 187, 2117-2125.	3.4	20
30	SPP1 rs4754 and its epistatic interactions with SPARC polymorphisms in gastric cancer susceptibility. Gene, 2018, 640, 43-50.	2.2	19
31	The Diagnostic Value of Serum PIVKA-II Alone or in Combination with AFP in Chinese Hepatocellular Carcinoma Patients. Disease Markers, 2021, 2021, 1-9.	1.3	19
32	<i>IDH1</i> mutation detection by droplet digital PCR in glioma. Oncotarget, 2015, 6, 39651-39660.	1.8	18
33	With or without reirradiation in advanced local recurrent nasopharyngeal carcinoma: a case–control study. BMC Cancer, 2016, 16, 774.	2.6	17
34	Risk stratification for nasopharyngeal carcinoma: a real-world study based on locoregional extension patterns and Epstein-Barr virus DNA load. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592093205.	3.2	17
35	The Frequency and Clinical Implication of ROS1 and RET Rearrangements in Resected Stage IIIA-N2 Non-Small Cell Lung Cancer Patients. PLoS ONE, 2015, 10, e0124354.	2.5	17
36	Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in stage III-IVb nasopharyngeal carcinoma patients with Epstein-Barr virus DNA ≥4000 copies/ml: a matched study. Oncotarget, 2016, 7, 29739-29748.	1.8	15

#	Article	IF	CITATIONS
37	<p>Mutation spectrum of germline cancer susceptibility genes among unselected Chinese colorectal cancer patients</p> . Cancer Management and Research, 2019, Volume 11, 3721-3739.	1.9	15
38	Comparison of the treatment outcomes of intensity-modulated radiotherapy and two-dimensional conventional radiotherapy in nasopharyngeal carcinoma patients with parapharyngeal space extension. Radiotherapy and Oncology, 2015, 116, 167-173.	0.6	14
39	LOX expression in primary nasopharyngeal carcinoma: correlation with prognostic parameters and outcome. Oncotarget, 2016, 7, 8200-8207.	1.8	14
40	Pretreatment quality of life as a predictor of survival for patients with nasopharyngeal carcinoma treated with IMRT. BMC Cancer, 2018, 18, 114.	2.6	13
41	Prognostic implications of a molecular classifier derived from wholeâ€exome sequencing in nasopharyngeal carcinoma. Cancer Medicine, 2019, 8, 2705-2716.	2.8	13
42	Classification of gastric cancer by EBV status combined with molecular profiling predicts patient prognosis. Clinical and Translational Medicine, 2020, 10, 353-362.	4.0	13
43	<i>ALK</i> gene copy number gain and its clinical significance in hepatocellular carcinoma. World Journal of Gastroenterology, 2014, 20, 183.	3.3	13
44	Clinicopathologic characteristics and therapeutic responses of Chinese patients with non-small cell lung cancer who harbor an anaplastic lymphoma kinase rearrangement. Chinese Journal of Cancer, 2015, 34, 404-12.	4.9	12
45	Comparison of KRAS mutation status between primary tumor and metastasis in Chinese colorectal cancer patients. Medical Oncology, 2016, 33, 71.	2.5	12
46	Hypermethylation of APC2 Is a Predictive Epigenetic Biomarker for Chinese Colorectal Cancer. Disease Markers, 2018, 2018, 1-7.	1.3	9
47	Interfering Expression of Chimeric Transcript <i> SEPT7P2-PSPH</i> Promotes Cell Proliferation in Patients with Nasopharyngeal Carcinoma. Journal of Oncology, 2019, 2019, 1-10.	1.3	9
48	Identification of a Gene-Related Risk Signature in Melanoma Patients Using Bioinformatic Profiling. Journal of Oncology, 2020, 2020, 1-13.	1.3	8
49	Inhibition of MiR-155 suppresses cell migration in nasopharyngeal carcinoma through targeting ZDHHC2. International Journal of Clinical and Experimental Medicine, 2015, 8, 8472-84.	1.3	7
50	Identification of surrogate endpoints in patients with locoregionally advanced nasopharyngeal carcinoma receiving neoadjuvant chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone. BMC Cancer, 2015, 15, 930.	2.6	6
51	Development and validation of a prognostic nomogram for the pre-treatment prediction of early metachronous metastasis in endemic nasopharyngeal carcinoma: a big-data intelligence platform-based analysis. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592097813.	3.2	6
52	Plasma SGIP1 methylation in diagnosis and prognosis prediction in hepatocellular carcinoma. Neoplasma, 2021, 68, 62-70.	1.6	5
53	Implication of comorbidity on the initiation of chemotherapy and survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma. Oncotarget, 2017, 8, 10594-10601.	1.8	5
54	Incidence of and Risk Factors for Mastoiditis after Intensity Modulated Radiotherapy in Nasopharyngeal Carcinoma. PLoS ONE, 2015, 10, e0131284.	2.5	4

#	Article	IF	CITATIONS
55	Predictors of Mastoiditis after Intensity-Modulated Radiotherapy in Nasopharyngeal Carcinoma: A Dose-Volume Analysis. Journal of Cancer, 2016, 7, 276-282.	2.5	4
56	Prognostic effect of pregnancy on young female patients with nasopharyngeal carcinoma: results from a matched cohort analysis. Oncotarget, 2016, 7, 21913-21921.	1.8	4
57	The Percentage of Anaplastic Lymphoma Kinase-Positive Tumor Cells Has Clinical Implications for Patients with Non-Small Cell Lung Cancer. Genetic Testing and Molecular Biomarkers, 2019, 23, 589-597.	0.7	3
58	Diagnostic and Prognostic Characteristics of Circulating Free DNA Methylation Detected by the Electrochemical Method in Malignant Tumors. Cancers, 2021, 13, 664.	3.7	3
59	Prognostic Implications of Tripartite Motif Containing 24 Expression Levels in Patients with Solid Tumors: A Systematic Review and Meta-Analysis. Genetic Testing and Molecular Biomarkers, 2019, 23, 473-479.	0.7	1
60	Performance of common genetic variants in risk prediction for colorectal cancer in Chinese: A two-stage and multicenter study. Genomics, 2021, 113, 867-873.	2.9	1